{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:13:21Z","timestamp":1792761201793,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,11,10]],"date-time":"2012-11-10T00:00:00Z","timestamp":1352505600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genet"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Hypertrophic Cardiomyopathy (HCM) is a genetically heterogeneous disease. One specific mutation in the <jats:italic>MYBPC3<\/jats:italic> gene is highly prevalent in center east of France giving an opportunity to define the clinical profile of this specific mutation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>HCM probands were screened for mutation in the <jats:italic>MYH7<\/jats:italic>, <jats:italic>MYBPC3<\/jats:italic>, <jats:italic>TNNT2<\/jats:italic> and <jats:italic>TNNI3<\/jats:italic> genes. Carriers of the <jats:italic>MYBPC3<\/jats:italic> IVS20-2A&gt;G mutation were genotyped with 8 microsatellites flanking this gene. The age of this <jats:italic>MYBPC3<\/jats:italic> mutation was inferred with the software ESTIAGE. The age at first symptom, diagnosis, first complication, first severe complication and the rate of sudden death were compared between carriers of the IVS20-2 mutation (group A) and carriers of all other mutations (group B) using time to event curves and log rank test.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Out of 107 HCM probands, 45 had a single heterozygous mutation in one of the 4 tested sarcomeric genes including 9 patients with the <jats:italic>MYBPC3<\/jats:italic> IVS20-2A&gt;G mutation. The IVS20-2 mutation in these 9 patients and their 25 mutation carrier relatives was embedded in a common haplotype defined after genotyping 4 polymorphic markers on each side of the <jats:italic>MYBPC3<\/jats:italic> gene. This result supports the hypothesis of a common ancestor. Furthermore, we evaluated that the mutation occurred about 47 generations ago, approximately at the 10th century.<\/jats:p>\n            <jats:p>We then compared the clinical profile of the IVS20-2 mutation carriers (group A) and the carriers of all other mutations (group B). Age at onset of symptoms was similar in the 34 group A cases and the 73 group B cases but group A cases were diagnosed on average 15\u2009years later (log rank test p\u2009=\u20090.022). Age of first complication and first severe complication was delayed in group A vs group B cases but the prevalence of sudden death and age at death was similar in both groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>A founder mutation arising at about the 10th century in the <jats:italic>MYBPC3<\/jats:italic> gene accounts for 8.4% of all HCM in center east France and results in a cardiomyopathy starting late and evolving slowly but with an apparent risk of sudden death similar to other sarcomeric mutations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2350-13-105","type":"journal-article","created":{"date-parts":[[2012,11,10]],"date-time":"2012-11-10T09:14:41Z","timestamp":1352538881000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["A human MYBPC3 mutation appearing about 10 centuries ago results in a hypertrophic cardiomyopathy with delayed onset, moderate evolution but with a risk of sudden death"],"prefix":"10.1186","volume":"13","author":[{"given":"Carolien H","family":"Teirlinck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fa\u00efza","family":"Senni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajae El","family":"Malti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Majoor-Krakauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Fellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Millat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Andr\u00e9-Fou\u00ebt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Pernot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u00ebl","family":"Stumpf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Boutarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Bouvagnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,10]]},"reference":[{"key":"1018_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","volume":"92","author":"BJ Maron","year":"1995","unstructured":"Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, et al: Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995, 92: 785-789. 10.1161\/01.CIR.92.4.785.","journal-title":"Circulation"},{"key":"1018_CR2","first-page":"1445","volume":"22","author":"D Brito","year":"2003","unstructured":"Brito D, Richard P, Isnard R, Pipa J, Komajda M, et al: Familial hypertrophic cardiomyopathy: the same mutation, different prognosis. Comparison of two families with a long follow-up. Rev Port Cardiol. 2003, 22: 1445-1461.","journal-title":"Rev Port Cardiol"},{"key":"1018_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1136\/heart.87.2.169","volume":"87","author":"WJ McKenna","year":"2002","unstructured":"McKenna WJ, Behr ER: Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart. 2002, 87: 169-176. 10.1136\/heart.87.2.169.","journal-title":"Heart"},{"key":"1018_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jama.1996.03540030033028","volume":"276","author":"BJ Maron","year":"1996","unstructured":"Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, et al: Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA. 1996, 276: 199-204. 10.1001\/jama.1996.03540030033028.","journal-title":"JAMA"},{"key":"1018_CR5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1161\/CIRCULATIONAHA.104.522581","volume":"112","author":"HL Tan","year":"2005","unstructured":"Tan HL, Hofman N, van Langen IM, van der Wal AC, Wilde AA: Sudden unexplained death: heritability and diagnostic yield of cardiological and genetic examination in surviving relatives. Circulation. 2005, 112: 207-213. 10.1161\/CIRCULATIONAHA.104.522581.","journal-title":"Circulation"},{"key":"1018_CR6","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0735-1097(03)00855-6","volume":"42","author":"BJ Maron","year":"2003","unstructured":"Maron BJ, Casey SA, Hauser RG, Aeppli DM: Clinical course of hypertrophic cardiomyopathy with survival to advanced age. J Am Coll Cardiol. 2003, 42: 882-888. 10.1016\/S0735-1097(03)00855-6.","journal-title":"J Am Coll Cardiol"},{"key":"1018_CR7","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jama.281.7.650","volume":"281","author":"BJ Maron","year":"1999","unstructured":"Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, et al: Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA. 1999, 281: 650-655. 10.1001\/jama.281.7.650.","journal-title":"JAMA"},{"key":"1018_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1083\/jcb.201101100","volume":"194","author":"PA Harvey","year":"2011","unstructured":"Harvey PA, Leinwand LA: The cell biology of disease: cellular mechanisms of cardiomyopathy. J Cell Biol. 2011, 194: 355-365. 10.1083\/jcb.201101100.","journal-title":"J Cell Biol"},{"key":"1018_CR9","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1161\/01.CIR.0000066323.15244.54","volume":"107","author":"P Richard","year":"2003","unstructured":"Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, et al: Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003, 107: 2227-2232. 10.1161\/01.CIR.0000066323.15244.54.","journal-title":"Circulation"},{"key":"1018_CR10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.4065\/80.4.463","volume":"80","author":"SL Van Driest","year":"2005","unstructured":"Van Driest SL, Ommen SR, Tajik AJ, Gersh BJ, Ackerman MJ: Sarcomeric genotyping in hypertrophic cardiomyopathy. Mayo Clin Proc. 2005, 80: 463-469. 10.4065\/80.4.463.","journal-title":"Mayo Clin Proc"},{"key":"1018_CR11","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1113\/jphysiol.2010.188482","volume":"588","author":"MH Meisler","year":"2010","unstructured":"Meisler MH, O\u2019Brien JE, Sharkey LM: Sodium channel gene family: epilepsy mutations, gene interactions and modifier effects. J Physiol. 2010, 588: 1841-1848. 10.1113\/jphysiol.2010.188482.","journal-title":"J Physiol"},{"key":"1018_CR12","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1161\/CIR.0b013e318223e230","volume":"124","author":"BJ Gersh","year":"2011","unstructured":"Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, et al: 2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation. 2011, 124: 2761-2796.","journal-title":"Circulation"},{"key":"1018_CR13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/dnares\/9.5.173","volume":"9","author":"M Shimizu","year":"2002","unstructured":"Shimizu M, Kosaka N, Shimada T, Nagahata T, Iwasaki H, et al: Universal fluorescent labeling (UFL) method for automated microsatellite analysis. DNA Res. 2002, 9: 173-178. 10.1093\/dnares\/9.5.173.","journal-title":"DNA Res"},{"key":"1018_CR14","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/ejhg.2008.3","volume":"16","author":"G Lesca","year":"2008","unstructured":"Lesca G, Genin E, Blachier C, Olivieri C, Coulet F, et al: Hereditary hemorrhagic telangiectasia: evidence for regional founder effects of ACVRL1 mutations in French and Italian patients. Eur J Hum Genet. 2008, 16: 742-749. 10.1038\/ejhg.2008.3.","journal-title":"Eur J Hum Genet"},{"key":"1018_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ejmg.2010.07.007","volume":"53","author":"G Millat","year":"2010","unstructured":"Millat G, Bouvagnet P, Chevalier P, Dauphin C, Jouk PS, et al: Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy. Eur J Med Genet. 2010, 53: 261-267. 10.1016\/j.ejmg.2010.07.007.","journal-title":"Eur J Med Genet"},{"key":"1018_CR16","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1136\/jcp.2004.021642","volume":"58","author":"B Yu","year":"2005","unstructured":"Yu B, Sawyer NA, Caramins M, Yuan ZG, Saunderson RB, et al: Denaturing high performance liquid chromatography: high throughput mutation screening in familial hypertrophic cardiomyopathy and SNP genotyping in motor neurone disease. J Clin Pathol. 2005, 58: 479-485. 10.1136\/jcp.2004.021642.","journal-title":"J Clin Pathol"},{"key":"1018_CR17","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S0735-1097(98)00448-3","volume":"32","author":"P Jaaskelainen","year":"1998","unstructured":"Jaaskelainen P, Soranta M, Miettinen R, Saarinen L, Pihlajamaki J, et al: The cardiac beta-myosin heavy chain gene is not the predominant gene for hypertrophic cardiomyopathy in the Finnish population. J Am Coll Cardiol. 1998, 32: 1709-1716. 10.1016\/S0735-1097(98)00448-3.","journal-title":"J Am Coll Cardiol"},{"key":"1018_CR18","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/S0195-668X(03)00466-4","volume":"24","author":"M Alders","year":"2003","unstructured":"Alders M, Jongbloed R, Deelen W, van den Wijngaard A, Doevendans P, et al: The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands. Eur Heart J. 2003, 24: 1848-1853. 10.1016\/S0195-668X(03)00466-4.","journal-title":"Eur Heart J"},{"key":"1018_CR19","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/S0735-1097(01)01387-0","volume":"38","author":"J Erdmann","year":"2001","unstructured":"Erdmann J, Raible J, Maki-Abadi J, Hummel M, Hammann J, et al: Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2001, 38: 322-330. 10.1016\/S0735-1097(01)01387-0.","journal-title":"J Am Coll Cardiol"},{"key":"1018_CR20","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/j.jacc.2005.05.087","volume":"46","author":"T Kubo","year":"2005","unstructured":"Kubo T, Kitaoka H, Okawa M, Matsumura Y, Hitomi N, et al: Lifelong left ventricular remodeling of hypertrophic cardiomyopathy caused by a founder frameshift deletion mutation in the cardiac Myosin-binding protein C gene among Japanese. J Am Coll Cardiol. 2005, 46: 1737-1743. 10.1016\/j.jacc.2005.05.087.","journal-title":"J Am Coll Cardiol"},{"key":"1018_CR21","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1136\/hrt.2010.200402","volume":"96","author":"MJ Oliva-Sandoval","year":"2010","unstructured":"Oliva-Sandoval MJ, Ruiz-Espejo F, Monserrat L, Hermida-Prieto M, Sabater M, et al: Insights into genotype-phenotype correlation in hypertrophic cardiomyopathy. Findings from 18 Spanish families with a single mutation in MYBPC3. Heart. 2010, 96: 1980-1984. 10.1136\/hrt.2010.200402.","journal-title":"Heart"},{"key":"1018_CR22","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s00109-002-0323-9","volume":"80","author":"P Jaaskelainen","year":"2002","unstructured":"Jaaskelainen P, Kuusisto J, Miettinen R, Karkkainen P, Karkkainen S, et al: Mutations in the cardiac myosin-binding protein C gene are the predominant cause of familial hypertrophic cardiomyopathy in eastern Finland. J Mol Med. 2002, 80: 412-422. 10.1007\/s00109-002-0323-9.","journal-title":"J Mol Med"},{"key":"1018_CR23","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1093\/eurheartj\/ehp306","volume":"30","author":"M Michels","year":"2009","unstructured":"Michels M, Soliman OI, Phefferkorn J, Hoedemaekers YM, Kofflard MJ, et al: Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers. Eur Heart J. 2009, 30: 2593-2598. 10.1093\/eurheartj\/ehp306.","journal-title":"Eur Heart J"}],"container-title":["BMC Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2350-13-105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2350-13-105\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2350-13-105","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2350-13-105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T21:27:11Z","timestamp":1630531631000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenet.biomedcentral.com\/articles\/10.1186\/1471-2350-13-105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,10]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1018"],"URL":"https:\/\/doi.org\/10.1186\/1471-2350-13-105","relation":{},"ISSN":["1471-2350"],"issn-type":[{"value":"1471-2350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,10]]},"assertion":[{"value":"8 May 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"105"}}